Memotext has inked a collaboration deal, a Memorandum of Understanding if you will with the Toronto-based Centre for Addiction and Mental Health. Together they will develop an app for people with schizophrenia and psychosis, according to a company statement.
In a phone interview with Memotext President and Founder Amos Adler, he said the app will function as part medication adherence monitor, part mental health barometer. To produce the app, Memotext formed a spinoff called A4i to provide a digital intervention for people newly diagnosed with schizophrenia and for “borderline cases”. It will reside at Johnson & Johnson’s latest center for innovation in Toronto, as part of a competition it won recently.
In a phone interview with Memotext President and Founder Amos Adler, he said the app will function as part medication adherence monitor, part mental health barometer. To produce the app, Memotext formed a spinoff called A4i to provide a digital intervention for people newly diagnosed with schizophrenia and for “borderline cases”. It will reside at Johnson & Johnson’s latest center for innovation in Toronto, as part of a competition it won recently.
